Key Takeaway: Tirzepatide targets two metabolic receptors (GLP-1/GIP) to offer up to 20.9% average weight loss, while Retatrutide attacks fat storage via three pathways (GLP-1/GIP/Glucagon), yielding unprecedented weight loss averages near 24.2% in Phase 2 trials
Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus
A 2024 commentary in Lancet Diabetes & Endocrinology reported that GLP-1 users can lose anywhere from 25 to 39% of their muscle mass over a 9-to-18-month period, which is a rate of decline several times greater than normal age-related muscle loss
These prospective studies will provide definitive evidence about whether these medications can prevent or slow cognitive decline in high-risk populations
In real-world practice, several patients can all ask about the same medication and still need very different plans: One may have significant GI sensitivity and need slower escalation
Yes, but only certain methods have demonstrated meaningful results, and it helps to sort them into three categories: lifestyle improvements that optimize erectile function, medically supervised non-surgical treatments, and surgery for selected patients
